Last reviewed · How we verify
CAPE-S
At a glance
| Generic name | CAPE-S |
|---|---|
| Also known as | CAPE solution |
| Sponsor | Ege University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Amenorrhea
- Pelvic pain
- Intermenstrual bleeding
- Headache
- Weight gain
- Irregular/heavy uterine bleeding
- Lower back pain
- Dysmenorrhea
- Enlarged Abdomen
- Menorrhagia
- Leukorrhea
- Cervicitis
Key clinical trials
- Comparison of Two Intrauterine Devices (IUDs) Among Cape Town HIV-positive Women (NA)
- The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors (PHASE1, PHASE2)
- A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
- Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma (PHASE3)
- Effect of Caffeic Acid Phenethyl Ester as a Matrix Metalloproteinase Inhibitor: Randomized Controlled Clinical Trial (NA)
- Impact of Medical Follow-up Discharge Package (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |